Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Bladder Cancer

10 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Basic Science

    VICCURO1322

    03/28/2014

    Vanderbilt Assessment of Shed ALCAM in Urogenital Cancers (VanSA)

    Other

    VICCURO15108

    05/31/2016

    Urinary Biomarkers in the Detection of Transitional Cell Carcinoma of the Bladder

    Other

    VICCURO1618

    05/24/2016

    Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma A Multicenter, Prospective Blinded Pivotal Study

    Treatment

    VICCURO1723

    08/10/2017

    An Open Label, Multicenter, Single Arm Phase II Pilot Study to Evaluate the Efficacy and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract whose Tumors Harbor a TSC1 and/or a TSC2 Mutation

    Treatment

    VICCGI15126

    05/03/2016

    A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

    Treatment

    ECOGUROS1314

    01/18/2016

    A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer

    Treatment

    VICCPHI1588

    11/27/2015

    A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

    Treatment

    VICCHEMP1558

    10/09/2015

    A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

    Treatment

    ECOGUROEA8141

    08/27/2015

    A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma

    Treatment

    VICCMD1403

    06/02/2014

    An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification


    Print this page for your doctor